Live Breaking News & Updates on Debra Birnkrant

Stay updated with breaking news from Debra birnkrant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA approves new, less intrusive treatment for HIV | National

After six months of treatment, about 80% of patients who were formerly at high viral load were at undetectable levels ....

United States , San Francisco , Debra Birnkrant , Sorana Segal Maurer , Division Of Antivirals , Drug Administration , Ryan White , Drug Evaluation , Antiretroviral Drug , Food And Drug Administration , Subcutaneous Injection ,

Hope as FDA approves injectable drug for resistant HIV

The medicine to be administered twice a year is retailing at Sh5.1 million currently. ....

Debra Birnkrant , Division Of Antivirals , Drug Evaluation , Hiv Aids , Amina Wako ,

FDA approves twice-yearly HIV treatment :: Bay Area Reporter

There is a new long-acting drug for people with highly resistant HIV who have, until now, had limited medication options. ....

Debra Birnkrant , Sorana Segal Maurer , Division Of Antivirals , Drug Administration , Gilead Science Sunlenca , Drug Evaluation , Viiv Healthcare , Opportunistic Infections , Weill Cornell Medicine , Bay Area Reporter , San Francisco , Bay Area ,

FDA approves twice-yearly HIV treatment :: Bay Area Reporter

There is a new long-acting drug for people with highly resistant HIV who have, until now, had limited medication options. ....

Debra Birnkrant , Sorana Segal Maurer , Division Of Antivirals , Drug Administration , Gilead Science Sunlenca , Drug Evaluation , Viiv Healthcare , Opportunistic Infections , Weill Cornell Medicine ,

FDA approves twice-yearly HIV treatment :: Bay Area Reporter

There is a new long-acting drug for people with highly resistant HIV who have, until now, had limited medication options. ....

Debra Birnkrant , Sorana Segal Maurer , Division Of Antivirals , Drug Administration , Gilead Science Sunlenca , Drug Evaluation , Viiv Healthcare , Opportunistic Infections , Weill Cornell Medicine ,